Investing in healthcare through private equity
In this episode, Genevieve Cua speaks to Hui Yang Goh, Head of Alternative Investments for Asia, on the opportunities to invest in healthcare through private equity.
Healthcare costs have been globally increasing, and technology and innovation are seen as potential solutions to improve efficiency and reduce expenses.
Innovation often emerges from smaller companies and start-ups, which require funding primarily from private markets, driving the progress. The majority of value creation in the healthcare industry occurs during the product development stage, offering attractive investment opportunities, as evidenced by the high number of drugs approved by the FDA originating from small companies.
The industry benefits from a strong M&A market, with big pharmaceutical companies acquiring innovative start-ups, contributing to the resilient and stable growth of the biotech sector for over a decade.
Listen to the podcast to learn more about:
- Routes to invest in healthcare
- Growth drivers in healthcare investing
- Opportunities and risks of PE investing
- Healthcare themes with greatest potential
- Resilience of healthcare sector
- Sustainability and ESG considerations
About WealthBT Podcast
Learn to protect and grow your wealth in this podcast series for affluent individuals, hosted by The Business Times wealth editor Genevieve Cua and Pictet experts in selected episodes.
Listen to more episodes with Pictet experts
Get in touch with us
Alternatively, you can contact us by filling in the form below.
Form sent successfully
Wealth management insights
Technology & science · 20 Sept 2023
Technology’s ability to address the global healthcare challenge
The impact of new technologies on healthcare systems worldwide has only just begun. Key advantages include detecting diseases early, and greater personalised care. Both should result in better patient outcomes and could reduce the cost burden on providers.
Alternatives · 09 Oct 2024
GLP-1: Opportunity for humanity, risk for big pharma
New treatments for obesity could alleviate a global healthcare crisis, but also have the potential to disrupt some of the largest pharmaceutical incumbents.
